Single dose bromocriptine microcapsules in postpartum lactation inhibition. 1987

L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch

The clinical efficacy and safety of a single intramuscular injection of Parlodel LA, Pravidel 50 mg, were studied in the prevention of lactation in 10 postpartum women. The overall efficacy at the end of the 28 day observation period was very good in 8 postpartum women and good in 2 women and no rebound lactation occurred. The prolactin plasma levels decreased to normal levels within 4 days in 9 women. Menstrual bleeding occurred in 9 women 4 to 6 weeks after treatment. Laboratory data recorded in this study support that Pravidel is effective in suppressing postpartum lactation.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007774 Lactation The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. Lactation, Prolonged,Milk Secretion,Lactations, Prolonged,Milk Secretions,Prolonged Lactation,Prolonged Lactations
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females

Related Publications

L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
February 1972, The Australian & New Zealand journal of obstetrics & gynaecology,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
November 1995, British journal of obstetrics and gynaecology,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
April 1981, Obstetrics and gynecology,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
July 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
October 1977, Canadian Medical Association journal,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
June 1990, British journal of obstetrics and gynaecology,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
January 1994, Journal de gynecologie, obstetrique et biologie de la reproduction,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
January 1978, Acta endocrinologica. Supplementum,
L Svanberg, and I Lancranjan, and T Arvidsson, and B Andersch
August 1983, British journal of obstetrics and gynaecology,
Copied contents to your clipboard!